Back

A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C

30 August 2016 (15:43 - 15:51)
Organised by:
Congress Presentation Part of: Lipid-lowering agents - New perspectives Drug therapy ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Sukrut Shah

Rahway (United States of America)

5 More presentations in this session

Presentation thumbnail
Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study
Professor S. Yamashita (Izumisano, JP)
Abstract Slides
Presentation thumbnail
Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate
Doctor M. Blazing (Durham, US)
Abstract Slides
Presentation thumbnail
Clinical tolerability and safety profile of CER-001, a novel bio-engineered pre-beta HDL-mimetic, across the clinical development programs
Professor A. Corsini (Milan, IT)
Abstract Slides
Presentation thumbnail
Effect of pcsk9 antibodies on neurocognitive outcomes and improved survival in patients at higher risk: a meta-analysis of randomised controlled trials
Doctor M. Kolodziejczak (Bydgoszcz, PL)
Abstract Slides
Presentation thumbnail
Dose-response relationship between proton pump inhibitor use and associated risk of myocardial infarction: a nationwide cohort study
Doctor T. Sehested (Copenhagen, DK)
Abstract Slides

Access the full session

Session thumbnail
Lipid-lowering agents - New perspectives

The Event

Event poster

ESC Congress 2016

30 August 2016 15:43 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources